Business News • PR NewsWire • Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer

Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer

Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer

SAN FRANCISCO and ILLKIRCH, France, Dec. 16, 2010 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharm

View More : http://www.prnewswire.com/news-releases/jennerex-and-transgene-announce-initiation-of-clinical-trial-of-intravenous-jx-5...

Releted News by prnewswire

Watson and Richter Announce Exclusive License Agreement for Esmya™

Solarfun Expands North American Presence, Supporting Commitment to Growing Market

UK High Street Gambling With Stock Shortages in Crucial Christmas Shopping Period